BioNTech SE (BNTX)
- Previous Close
92.34 - Open
92.78 - Bid 92.53 x 100
- Ask 118.13 x 200
- Day's Range
91.79 - 93.17 - 52 Week Range
76.53 - 131.49 - Volume
733,600 - Avg. Volume
1,119,919 - Market Cap (intraday)
22.301B - Beta (5Y Monthly) 1.36
- PE Ratio (TTM)
-- - EPS (TTM)
-3.56 - Earnings Date Aug 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 2, 2022
- 1y Target Est
133.42
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
www.biontech.deRecent News: BNTX
View More
Performance Overview: BNTX
Trailing total returns as of 5/18/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BNTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BNTX
View MoreValuation Measures
Market Cap
22.30B
Enterprise Value
6.84B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.26
Price/Book (mrq)
1.05
Enterprise Value/Revenue
2.22
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-27.89%
Return on Assets (ttm)
-3.67%
Return on Equity (ttm)
-3.94%
Revenue (ttm)
2.75B
Net Income Avi to Common (ttm)
-766M
Diluted EPS (ttm)
-3.56
Balance Sheet and Cash Flow
Total Cash (mrq)
14.11B
Total Debt/Equity (mrq)
1.55%
Levered Free Cash Flow (ttm)
-335.98M
Research Analysis: BNTX
View MoreResearch Reports: BNTX
View MoreBioNTech Earnings: Guidance Reiterated, Oncology Development Continues to Advance
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
RatingPrice TargetBioNTech Earnings: Guidance Reiterated, Oncology Development Continues to Advance
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
RatingPrice TargetBioNTech Earnings: 2025 Guidance Disappoints, Fair Value Lowered
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
RatingPrice TargetBioNTech Earnings: 2025 Guidance Disappoints, Fair Value Lowered
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
RatingPrice Target